Swiss CDMO ten23 health increases its sterile production in Visp by 50% !

Swiss company ten23 health has just announced an increase in capacity for the manufacture of sterile pharmaceutical products (VIVA 1®) at its site at BioArk Viège (Valais). This extension will enable the company to meet growing demand from its customers for filling and finishing services for sterile products.

Increased storage space and visual inspection capabilities have already been announced (press release 19.09.2022). Once the Good Manufacturing Practice (GMP) inspection has been successfully completed by Swissmedic and the corresponding GMP license obtained, the new storage areas will become operational in September 2023. 

Production on ten23’s existing sterile manufacturing line (line 1) in Visp will be gradually increased by 50%, thanks to the hiring of additional staff to provide an extra shift. 

Two additional filling lines are already under construction!

In addition, as previously announced, further expansions of ten23’s pharmaceutical development and manufacturing services are underway at the company’s BASE® (Basel, Switzerland) and VIVA® (Visp, Switzerland) facilities, to meet growing industry demand for the development, testing and manufacture of complex sterile products. 

With VIVA 2®, ten23 is building two additional filling lines for sterile commercial supplies of syringes, cartridges and ready-to-use vials (line 2) and supplies of liquid or lyophilized clinical and commercial vials (line 3). The project is well underway, and a first customer project and technology transfer have been signed for manufacturing in 2024 and 2025.

We are delighted to be able to offer our customers additional sterile manufacturing capacity for sophisticated, high-precision drug presentations such as syringes and cartridges, increased capacity until the two new production lines become fully operational,” said Professor Dr Hanns-Christian Mahler, CEO of ten23 health. “With the recent increase in demand for clinical and commercial drug launches, our customers are keen to take advantage of the increased capacity of the existing VIVA 1® facility, before the new VIVA 2® plant is used for larger scales.


Source: ten23 health press release

4 September 2023
Scroll to Top